How to Write a Clinical Supply Plan: The 12 Sections Every Plan Needs

Most clinical supply problems are decided long before they happen — in a meeting where someone chose a packaging configuration, a country list, or a resupply strategy without writing down why. Months later, when a depot runs dry or a batch expires unused, nobody can reconstruct the assumptions that led there.

A clinical supply plan is the document that prevents that. Not a formality for the TMF, but the single place where every supply decision for a study is recorded alongside the assumption it rests on, the risk it carries, and the person who owns it. Done well, it's the most useful document a supply team produces. Done as a template exercise, it's forty pages nobody opens after kickoff.

What is a clinical supply plan?

A clinical supply plan is the study-level document that defines how investigational product, comparators, and ancillaries will get from manufacturing to patients for the life of a trial. It translates the protocol — arms, doses, visit schedule, countries, enrollment targets — into concrete decisions about manufacturing, packaging, labeling, distribution, IRT configuration, and risk management.

The test of a good plan is simple: a new supply manager joining mid-study should be able to read it and understand not only what was decided, but why, and what would trigger a change.

When should you write it?

Start drafting during protocol development, not after protocol approval. The decisions with the biggest cost impact — packaging design, dose strengths, visit windows that drive resupply, the country list — are cheapest to influence before the protocol is locked. A supply plan written after the fact documents constraints; one written alongside the protocol shapes them.

Treat the first version as a working draft at protocol synopsis, a baselined version before first packaging run, and a living document from then on.

What sections should a clinical supply plan include?

Here are the twelve sections we'd expect in any plan, and the question each one has to answer.

• 1 — Section: Study overview & supply assumptions; The question it answers: What protocol facts is supply built on — and which are still uncertain?
• 2 — Section: Product & stability profile; The question it answers: What are we shipping, how must it be stored, and how long will it last?
• 3 — Section: Packaging & labeling design; The question it answers: How is drug configured into kits, and how flexible is that design?
• 4 — Section: Demand forecast & scenarios; The question it answers: How much do we need under realistic, fast, and slow enrollment?
• 5 — Section: Manufacturing & packaging schedule; The question it answers: When is each batch made and packed, and what are the lead times?
• 6 — Section: Distribution network; The question it answers: Which depots serve which countries, and how does drug move?
• 7 — Section: IRT supply strategy; The question it answers: How will kits be assigned and sites resupplied automatically?
• 8 — Section: Comparators & ancillaries; The question it answers: What else do sites need, and who provides it?
• 9 — Section: Regulatory & import pathway; The question it answers: What labeling, release, and import requirements apply per country?
• 10 — Section: Quality & temperature control; The question it answers: How are storage, shipping, and excursions managed?
• 11 — Section: Risks & contingencies; The question it answers: What could break, and what's the pre-agreed response?
• 12 — Section: Governance, change control & budget; The question it answers: Who decides, how is the plan updated, and what will it cost?

A few notes on the sections that most often go wrong:

Section 1 — assumptions. List every assumption explicitly, with a confidence level: enrollment rate per site per month, screen-failure rate, dropout rate, dose-modification frequency, country activation dates. Every downstream number inherits these. If they're buried, nobody knows when they've been invalidated.

Section 4 — forecast. A single-point forecast is not a forecast. The plan should show a range of scenarios and state which one supply is being built to — and at what risk tolerance. Our demand forecast guide goes deeper.

Section 3 — packaging. Record not just the design but the flexibility it preserves or gives away: booklet labels or not, country pooling, expiry update approach. See our packaging and labeling strategy post for the trade-offs.

Section 7 — IRT. The plan should hold the intended buffer levels, resupply triggers, and prediction windows, with the rationale, so that the configured values can be checked against intent. Our post on IRT supply settings explains why these parameters matter so much.

Section 8 — ancillaries. Attach the ancillary bill of materials rather than a one-line reference to the pharmacy manual.

Section 11 — risks. Don't copy a generic register. Name the study's actual single points of failure — the one CDMO, the one depot, the one import license — and the pre-agreed response for each.

Who should own and approve the plan?

The clinical supply lead owns it. But a plan approved only by supply is a plan the rest of the study team hasn't committed to. At minimum, sign-off should include clinical operations (enrollment and country assumptions), CMC or technical operations (manufacturing and stability), quality (release and GMP/GDP), regulatory (labeling and import), and the IRT lead. If the study is outsourced, the CRO's supply counterpart should sign too.

The sign-off isn't bureaucracy. It's the moment each function confirms the assumptions attributed to them are actually theirs.

How do you keep a supply plan alive after kickoff?

Most plans die at the first amendment. The fix is to connect the plan to the study's operating rhythm:

• Review triggers, not just review dates: a protocol amendment, a new country, enrollment deviating from the base scenario by more than an agreed threshold, a stability update, a batch failure.
• A change log at the front of the document recording what changed, why, and who approved it.
• A monthly supply review that compares actuals — enrollment, consumption, site inventory, waste — against plan assumptions, and updates the assumptions when reality disagrees.
• Version discipline: one current version, in one location, referenced by everyone.

What are the most common mistakes?

• Writing the plan after the packaging design is already fixed.
• Recording decisions without the assumptions behind them.
• One forecast scenario, presented as fact.
• No explicit risk tolerance, so nobody knows whether the buffer is deliberate or accidental.
• Treating comparators and ancillaries as someone else's problem.
• No change control — the plan and the IRT configuration drift apart within weeks.